This Week in Family Medicine — Jun 5, 2026

Welcome to This Week in Family Medicine. This week we're covering notable papers spanning global public health, new therapeutic interventions for chronic disease, and a look at foundational science that may shape future practice. Let's dive in.

We start on the global stage, with three papers that provide a wide-angle view of public health challenges and successes. First, a remarkable analysis in The Lancet Global Health celebrates the 50th anniversary of the Expanded Programme on Immunization, or EPI [2]. Researchers evaluated the economic impact of immunization against 14 pathogens across 194 countries over the past 50 years. The results are staggering. The program, which cost just under one trillion dollars, generated over 15 trillion dollars in benefits from averted productivity losses. This yields a benefit-cost ratio of 16, meaning every dollar invested returned 16 dollars to the global economy, making the program overwhelmingly cost-saving. While all 14 vaccines showed favorable outcomes, the measles vaccine was the star performer, with a benefit-cost ratio of nearly 74. The study confirms that the EPI has been a phenomenal investment in global health, with the highest returns seen in low-income countries.

Despite this success, a comprehensive analysis in the BMJ highlights new and persistent challenges in child and adolescent mortality [1]. Looking at global data from 2000 to 2024 for those aged 5 to 19, the study finds that the leading cause of death is now road traffic injuries, accounting for over 113,000 deaths in 2024. This is followed by malaria and neoplasms. The patterns differ starkly by age and sex. In younger children aged 5 to 14, communicable and nutritional conditions still make up nearly half of all deaths. But for adolescents aged 15 to 19, injuries and violence dominate. For older male adolescents, road traffic injuries are the top killer, while for older female adolescents, self-harm is the most prevalent cause of death. Worryingly, the paper notes that the decline in mortality from many communicable diseases has slowed since 2015, suggesting that maintaining progress is becoming more challenging and requires new focus on previously lower-priority areas like non-communicable diseases in this age group.

Adding another layer to this global picture, a paper in Nature Medicine investigates the gap between healthcare access and healthcare quality [6]. Researchers looked at three 'Exemplar' countries—Nepal, Senegal, and Zambia—which are recognized for making outstanding progress in maternal and newborn health. They found a stark 'quality gap' in childbirth care. While crude coverage of births attended by skilled health personnel ranged from 30% to as high as 100% in some regions, the 'effective' coverage—that is, the proportion of births receiving genuinely life-saving, high-quality care—was dramatically lower, ranging from just 12% to 43%. The authors conclude that even in some of the highest-performing health systems in the low- and middle-income world, mothers and newborns are receiving far less life-saving care than the coverage statistics would suggest, emphasizing that improving quality, not just access, is critical to reducing mortality.

Next, we turn to two studies evaluating interventions that could directly change how we manage complex chronic conditions. First, a study in The Lancet brings important news for patients with primary progressive multiple sclerosis, or PPMS [9]. The ORATORIO-HAND trial was a phase 3b study designed to see if ocrelizumab works in a broader, more representative PPMS population, including older patients up to age 65 and those with more advanced disability. The study found that ocrelizumab was superior to placebo, reducing the risk of composite disability progression by 30% over 144 weeks. The effect was particularly strong for preserving hand function, a key outcome for this patient group. The safety profile was manageable, with a slightly higher rate of infections that was not present after excluding COVID-19. These findings support the use of ocrelizumab in a wider range of patients with PPMS than originally studied.

From a high-tech infusion to a foundational intervention, our next paper in Nature Medicine evaluates the impact of medically tailored meals, a key 'food is medicine' therapy [8]. This large-scale evaluation looked at a Massachusetts Medicaid demonstration, comparing over 1,800 recipients of medically tailored meals to a similar group of over 1,300 non-recipients. Both groups had diet-related conditions and food insecurity. The results were dramatic. After an average of about 7 months, receipt of medically tailored meals was associated with 31% fewer hospitalizations and 20% fewer emergency department visits. Critically, the associated healthcare cost reductions of over $3,400 per person offset 98% of the meal program's cost. For participants with cardiovascular disease, chronic kidney disease, depression, diabetes, or high comorbidity, the program was actually net cost-saving. This provides powerful, real-world evidence for integrating nutrition services into clinical care for high-risk populations.

Finally, we'll briefly touch on three papers from the journal Nature that pull back the curtain on fundamental cellular processes. While not immediately practice-changing, they point to where future therapies might come from. One study identifies spermine, a naturally occurring polyamine, as an endogenous iron chelator that protects cells from a form of iron-dependent cell death called ferroptosis [3]. This discovery could have implications for protecting organs like the liver, intestine, and kidneys from ischemia-reperfusion injury. A second paper uncovers a fascinating cellular repair mechanism for lysosomes, the cell's recycling centers [5]. When a lysosome is damaged, a protein complex the researchers named LASER is rapidly assembled. This complex senses the damage and recruits the ESCRT machinery to patch the membrane. Defects in this system are implicated in hereditary spastic paraplegia, linking this basic mechanism to neurodegenerative disease. And a third paper uses advanced single-nucleus sequencing to map how IDH-mutant gliomas evolve and recur after treatment [4]. It identifies distinct malignant cell states and traces how they change in response to therapy and the tumor microenvironment, providing a detailed roadmap of glioma progression that could one day inform more targeted treatments.

If you only have time for one paper this week, make it the study on medically tailored meals in Nature Medicine [8]. Its findings are directly relevant to the complex, real-world challenges we face in family medicine, demonstrating that a non-pharmacologic, socially-oriented intervention can produce hard improvements in health outcomes and healthcare utilization, all while being nearly cost-neutral.

Here are the key takeaways from this week in Family Medicine: First, for your Medicaid patients with diet-related chronic diseases and food insecurity, consider that medically tailored meals are a powerful intervention. This week's evidence shows they can reduce hospitalizations by nearly a third and are cost-effective, even net cost-saving in many high-morbidity groups. Second, for patients with primary progressive MS, ocrelizumab is effective at slowing disability progression, even in older patients and those with more advanced disease. The benefit for preserving hand function is a particularly important counseling point. Third, when counseling adolescents and their families, remember that the epidemiology of mortality has shifted. Injury prevention, especially regarding road traffic, and screening for mental health challenges like self-harm are critical components of care for this age group. Fourth, remember that global health successes, like vaccination, are monumental, but we face new challenges. Progress has stalled in some areas, and a major 'quality gap' exists where access to care doesn't equal effective care, a crucial concept when interpreting health statistics.

That's your roundup for This Week in Family Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.